WO1990013629A1 - A method for the activation of t cells - Google Patents
A method for the activation of t cells Download PDFInfo
- Publication number
- WO1990013629A1 WO1990013629A1 PCT/US1990/002649 US9002649W WO9013629A1 WO 1990013629 A1 WO1990013629 A1 WO 1990013629A1 US 9002649 W US9002649 W US 9002649W WO 9013629 A1 WO9013629 A1 WO 9013629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- mhc class
- antibody
- cross
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000004913 activation Effects 0.000 title abstract description 19
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims abstract description 84
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims abstract description 84
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims abstract description 6
- 108010075704 HLA-A Antigens Proteins 0.000 claims abstract description 5
- 230000003213 activating effect Effects 0.000 claims abstract description 4
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims abstract 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims abstract 4
- 108010058607 HLA-B Antigens Proteins 0.000 claims abstract 4
- 108010052199 HLA-C Antigens Proteins 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims description 87
- 108091054437 MHC class I family Proteins 0.000 claims description 30
- 102000043129 MHC class I family Human genes 0.000 claims description 29
- 238000004132 cross linking Methods 0.000 claims description 24
- 241000283707 Capra Species 0.000 claims description 4
- 239000000427 antigen Substances 0.000 description 49
- 108091007433 antigens Proteins 0.000 description 49
- 102000036639 antigens Human genes 0.000 description 49
- 241000282414 Homo sapiens Species 0.000 description 23
- 108010002350 Interleukin-2 Proteins 0.000 description 21
- 102000000588 Interleukin-2 Human genes 0.000 description 21
- 230000035755 proliferation Effects 0.000 description 16
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 10
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 6
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- -1 phenylmethylsulfonyl Chemical group 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
Definitions
- This invention relates to a method for activating human T cells.
- the activation of T cells is believed to be of therapeutic importance in treating and fighting diseases such as cancer, viral infections, and autoimmune disorders.
- lymphocytes are the primary cells involved in generating an immune response.
- lymphocytes There are two principal classes of lymphocytes. One major class are the B cells which interact with soluble antigens, and produce and secrete specific antibodies.
- T cells The other class, T cells, consists of several subpopulations which regulate the immune response by direct cell-cell interactions and by producing and releasing in the blood a variety of lymphokines.
- B cells differentiate from hemato- poietic stem cells, probably in the bone marrow.
- T cells differentiate from hematopoietic stem cells which have migrated from the bone marrow to the thymus.
- differentiating T cells are known as thymocytes and express unique cell surface protein "markers" which are characteris ⁇ tic for every differentiation step, Reinherz and Schlossman, "The Differentiation and Function of Human T Lymphocytes", Cell, 19:821-827 (1980).
- T cells leave the thymus as long-lived small lymphocytes which circulate in the blood stream, lymphatic system and intercellular spaces.
- T cells have immunologic specificity, they can recognize and react with antigens and also distinguish between "self” and “non- self” during cell-mediated immune response (e.g., graft rejection) .
- TCR cell surface marker T cell receptor
- T cells express high levels of the cell surface marker T cell receptor (TCR) and are segregated into two major subclasses of CD4-positive and CD8-positive cell populations.
- T cells encounter an antigen which is recognized by the T cell receptor on their surface, they are stimulated to divide and proliferate so that many more T cells of the same antigen specificity are produced. This process of T-cell activation enables the activated T cells to perform different tasks.
- T cells Several subclasses of mature T cells have been recognized based on the different tasks they perform.
- Helper cells T, ) are required for promoting or enhancing B-cell antibody production.
- Cytotoxic/effector or killer cells T.
- Suppressor cells T ) suppress or down-regulate immunological reactions.
- Most of the T, cells express the CD4 antigen whereas the T J, and Ts cells express the CD8 antigen, Swain, "T-cell Subsets and the Recognition of MHC Class", Immunol. Rev., 7:129 (1983) .
- MHC antigens are expressed on most human cells. MHC is divided into three classes (I-III) of antigens, Steinmetz et al., "Genes of the Major Histocompatibility Complex in Mouse and Man", Science, 222:727 (1983). MHC class I antigens include human leukocyte antigens (HLA-A, -B and -C) . Recent reports suggest that on many cell types studied, there is a physical association between MHC antigens and other cell surface proteins with receptorial activities. The review article entitled, "Function by Association?”, M. Edidin, Immunology Today, 9:218-219 (1988) concludes that although there may be spatial associations between MHC Class I antigens and other T cell surface proteins, the function of these associations remains unknown.
- CD8 T cells expressing CD8 are herein designated CD8 cells.
- CD8 is thought to be involved in the process of T-cell recognition and activation, serving as an important element in MHC class I-restricted immune response.
- Engleman et al. "Activation of Human T Lymphocyte Subsets: Helper and Suppressor/Cytotoxic T cells Recognize and Respond to Distinct Histocompatibility Antigens", J. Immunol., 127:2124
- T cells are known to be activated when CD8 interacts on the cell surface with the T cell receptor complex, Emmrich et al., "Synergism in the Activation of Human CD8 T cells by Cross-linking the T-cell Receptor Complex With the CD8 Differentiation Antigen", Proc. Natl. Acad. Sci. USA, 83:8298 (1986). Nevertheless, the precise role of CD8 in T-cell recognition and activation remains unclear.
- CD8 and the MHC Class I heavy chain antigens have been found to be noncovalently associated on the surface of antigen- or mitogen-activated human T cells but the functional role of this molecular complex was not determined, Bushkin et al., "Physical Association Between. CD8 and HLA Class I Molecules on the Surface of Activated Human T Lymphocytes", Proc. Nat'l. Acad. Sci. USA, 85:3985- 3989 (1988); and Blue et al. , "Evidence for Specific Association Between Class I Major Histocompatability Antigens and the CD8 Molecules on Human Suppressor/Cytoxic Cells", 54:413-421 (1988).
- Figure 1 shows the kinetics of proliferative responses of CD8-MHC class I cross-linked CD8 cells.
- This invention is based on the finding that noncovalent complexes of CD8 and MHC class I antigens are found on activated human cytotoxic/suppressor T cells.
- noncovalent cross-linking of CD8 and MHC class I antigens on the surface of resting CD8 cells can activate these T cells and stimulate their proliferation in response to for example interleukin-2 (IL-2) .
- Cross-linking of T cell surface molecules can be accomplished by any known means of associating molecules of this type.
- the use of primary antibodies or parts thereof which bind to T cell surface proteins and subsequent cross-linking of the primary antibodies with secondary antibodies serves to noncovalently associate T cell surface proteins.
- hetero-conjugate (hybrid) antibodies can be generated by chemical cross-linking of anti-CD8 and anti-MHC class I antibodies, or by "hybrid" hybridomas obtained by the fusion of parental hybridomas secreting anti-CD8 and anti-MHC class I antibodies.
- CD8 and MHC class I antigens on the same activated CD8 cell are noncovalently associated.
- any means of covalent association such as that achieved by chemical cross-linking could also be used.
- cross-linking of CD8 and MHC class I antigens on a CD8 cell is accomplished by a two step method.
- the first step is to incubate a CD8 cell sample with at least one of the monoclonal antibodies (mAb) specific for CD8 (C8, OKT8A and anti-Leu-2a) and with at least one of the mAb specific for MHC class I antigens (PA2.6, BB7.7 and A1.4).
- the first set, or primary, mAb are allowed to bind to their respective antigens (CD8 and MHC class I) and then the excess, unbound, mAb is washed away from the cells.
- the mAbs bound to the CD8 and MHC class I antigens on the cell surface are brought into close proximity to cause a noncovalent association of CD8 and MHC class I antigens.
- a secondary antibody is a polyclonal affinity- purified goat anti-mouse IgG (GaMIg) antibody which recognizes and binds to the unbound Fc-portion of the primary mAb.
- GaMIg polyclonal affinity- purified goat anti-mouse IgG
- the noncovalent association between CD8 and MHC class I antigens approximated by anti-CD8, anti-MHC class I and secondary antibodies is due to some degree of structural homology between CD8 and MHC class I antigens, Littman et al.
- Cross-linking of CD8 and MHC class I antigens as described above results in a marked proliferation of resting human CD8 cells in the presence of IL-2.
- CD8 cell activation and proliferation can also be induced by cross-linking of MHC class I antigens to themselves (Fig. 1 and Table I) .
- Activation of CD8 cells by cross-linking of CD8 and MHC class I antigens is accompanied by expression of both IL-2 receptor and the MHC class II (HLA-DR and -DQ) antigens as demonstrated by immunoprecipitation and sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The presence of these antigens is indicative of the T-cell activation.
- Activation of CD8 cells by cross-linking is apparently independent of accessory monocytes.
- Various anti-CD8 and anti-MHC class I mAb which recognize nonpolymorphic antigenic determinants can be used to activate CD8 cells.
- not all mAb induce proliferation to the same extent.
- PA2.6, BB7.7 and A1.4 mAb together with anti-CD8 mAb markedly stimulated the proliferation of CD8 cells, W6/32 mAb showed a weak stimulation, whereas BBM.l, Ql/28 and HC10 mAbs failed to induce proliferation (Table II) .
- CD8 cells activated in such a way become functionally competent cytotoxic and/or suppressor T cells.
- This novel method of T-cell activation could therefore be of great importance in generating activated T cells for therapeutic purposes, similar to the use of lymphokine-activated killer and tumor-infiltrating T lymphocytes in cancer therapy, Oehoa et al., "Lymphokine- Activated Killer Activity in Long-Term Cultures with Anti- CD3 Plus Interleukin 2: Identification and Isolation of Effector Subsets", Cancer Research, 49:963-968 (1989); and Rosenberg et al.
- cytotoxic effector T cells generated by cross-linking of CD8 and MHC class I antigens may be used in the treatment of cancer and viral infections in mammals including humans, whereas suppressor T cells activated in this manner may be effective in the treatment of autoimmune diseases.
- CD8-MHC class I molecular complex on the T cell surface may serve as a marker for certain stages of T-cell activation, and as such, be useful in clinical diagnosis of various disease states and in the follow-up control of various anti-cancer and immunodeficiency treatments.
- T cells could be activated both in vitro and in vivo in mammals including humans.
- activation of human T cells in vivo would require some modifications, for example, hybrid anti-CD8/MHC class I mAb, if used, would need to be produced by human hybridomas rather than by murine hybridomas.
- Peripheral blood mononuclear cells were isolated from buffy coats of healthy donors by gradient centrifugation on Ficoll-Hypaque (Isolymph, Gallard- Schlesinger Chemical Mfg. Corp. , Carle Place, NY) .
- T lymphocytes were separated from non-T cells by rosetting with neuraminidase (Sigma)-treated sheep red blood cells at 4°C for 1 hr. , Kansas et al., "Functional Characterization of Human T Lymphocyte Subsets Distinguished by Monoclonal Anti-Leu8", J. Immunol., 134:2995 (1985).
- Nonadhered CD8 cells were collected, and contaminating monocytes were depleted by repeated adherence to tissue culture flasks at 37°C. Monocytes were further depleted by treatment with L243 mAb (IgG2a) at 4°C for 30 min, and then with 10% rabbit complement (Low-Tox-H, Cedarlane Laboratories, Ontario, Canada) at 37°C for 1 hr with frequent agitation.
- L243 mAb IgG2a
- rabbit complement Liow-Tox-H, Cedarlane Laboratories, Ontario, Canada
- the phenotypic profile of the purified CD8 cells was determined by fluorescence activated cell sorter (FACS) analysis (Ortho System 50H Cytofluoro- graph, Ortho Diagnostics Systems, Inc., Westwood, MA) and was determined to be as follows: >90% CD8 , >93% CD3 , ⁇ 8%
- the purified CD8 cells prepared according to Example 1 were suspended at 10 cells/ml in RPMI 1640 medium supplemented with 10% fetal bovine serum, glutamine (0.06 mg/ml) , streptomycin (0.1 mg/ml) and penicillin (100 U/ml) (hereafter, culture medium) and were incubated with 10-15 ⁇ g/ml of various mAb for 1 hr at room temperature.
- 0KT8A IgG2a, Ortho Diagnostics, Raritan, NJ
- anti-Leu-2a IgGl, Becton Dickinson, Mt. view, CA
- C8 IgG2a, Dr. C.Y. Wang, United Biomedical, Lake Success, NY
- W6/32 IgG2a
- PA2.6 IgGl
- BB7.7 IgG2b
- ATCC American Type Culture Collection
- BBM.l (ATCC) is an IgG2b mAb recognizing ⁇ -microglobulin ( ⁇ 2 ⁇ ) . All anti-CD8 and anti- MHC class I antigen mAb were equilibrated with respect to the concentration of mouse immunoglobulin.
- cells were washed twice and seeded in flat-bottomed 96-well microtiter plates at 5x10 4 or 1x105 cells/ well i.n 200 ⁇ l culture medium.
- affinity-purified GaMIg (Organon
- CD8 and MHC class I molecules on the surface of CD8 cells were cross-linked. This was done by first incubating CD8 cells prepared according to Example 1 with anti-CD8 and/or anti-MHC class I mAb, and then reacting with GaMIg as described in Example 2.
- CD8-MHC class I cross-linked cells markedly proliferated in response to IL-2 as determined by [ H]TdR uptake.
- Both GaMIg and IL-2 are essential for the proliferation of CD8 cells.
- the effect of IL-2 on CD8 cell proliferation is dose-dependent: an increase in IL-2 concentration from 10 U/ml to 100 U/ml resulted in an up to 8-fold increase in cell proliferation.
- the proliferation of CD8 cells also depends on the concentration of GaMIg added, with as little as 0.25 ⁇ g/ral of GaMIg inducing a 3-fold increase in T cell proliferation.
- GaMIg IL-2 none C8 A1.4 C8+A1.4
- CD8 cell population vigorously depleted of monocytes by treatment with L243 mAb and complement, also proliferated after cross-linking of CD8 and MHC class I antigens, suggesting that the activation of CDS cells is independent of accessory cells. It was noted, however, that addition of a small quantity of autologous monocytes to these cells dramatically increased their proliferative response, perhaps due to an IL-2-mediated, monocyte- dependent T cell proliferation.
- CD8 cells were first incubated in culture medium alone (+) , with OKT3 (open triangle) , C8
- Example 4 (open square), A1.4 (black triangle) or a mixture of C8 and A1.4 mAb (black square), then washed and cultured in the presence of GaMIg and IL-2 as described in Example 2. IL-2 was omitted in CD8 cells cross-linked with OKT3 mAb.
- Example 4
- T cells activated by antigen or mitogen express IL-2 receptor (IL-2R) and MHC class II anti- gens
- IL-2R IL-2 receptor
- MHC class II anti- gens Cotner et al., "Simultaneous Flow Cytometric Analysis of Human T-cell Activation Expression Antigen Expression and DNA Content", J. Exp. Med. , 157:461 (1983); and Robbins et al. , "Activated T Cells and Monocytes Have Characteristic Patterns of Class II Antigen Expression", J. Immunol., 141:1281 (1988).
- CD8-MHC class I cross-linked CD8 cells and control untreated CD8 cells were cultured in the presence or absence of GaMIg and/or IL-2 for 5 days as described in Example 2. The cells were then radioiodinated, and the cell lysates were reacted with anti-Tac (anti-IL- 2R) , and 1D1 and anti-Leu-io (anti-MHC class II) mAb followed by SDS-PAGE analysis. Radioiodination, immunoprecipitation and SDS-PAGE procedures are described in more detail as follows.
- C8 and/or various mAb specific for MHC class I antigen were cultured at 5x10 4 or 1x105 per well i.n culture medi.um in 96-well plates for 5 days in the presence of GaMIg and IL-2 as described in Example 2.
- PA2.6, BB7.7 and A1.4 mAb induced potent proliferation of CD8-MHC class I cross-linked CD8 cells.
- W6/32 mAb exerted a weak stimulatory effect.
- BBM.l, HC10 and Ql/28 mAb did not stimulate the cells.
Abstract
This invention relates to a method for activating CD8-positive T cells. The activation is achieved by forming an association between two T cell surface molecules such as CD8 and HLA-A, HLA-B, or HLA-C.
Description
DESCRIPTION
A METHOD FOR THE ACTIVATION OF T CELLS
BACKGROUND OF THE INVENTION
This work was partially supported by a grant from the National Institute of Health.
This invention relates to a method for activating human T cells. The activation of T cells is believed to be of therapeutic importance in treating and fighting diseases such as cancer, viral infections, and autoimmune disorders.
Immunity in vertebrates including man is the result of many complex cellular interactions. Although a variety of cells and humoral factors play a role in protecting an individual against foreign antigens, lymphocytes are the primary cells involved in generating an immune response.
There are two principal classes of lymphocytes. One major class are the B cells which interact with soluble antigens, and produce and secrete specific antibodies.
The other class, T cells, consists of several subpopulations which regulate the immune response by direct cell-cell interactions and by producing and releasing in the blood a variety of lymphokines. In mammals, B cells differentiate from hemato- poietic stem cells, probably in the bone marrow. T cells differentiate from hematopoietic stem cells which have migrated from the bone marrow to the thymus. There are several steps in the maturation of T cells. In the thymus,
differentiating T cells are known as thymocytes and express unique cell surface protein "markers" which are characteris¬ tic for every differentiation step, Reinherz and Schlossman, "The Differentiation and Function of Human T Lymphocytes", Cell, 19:821-827 (1980).
Mature T cells leave the thymus as long-lived small lymphocytes which circulate in the blood stream, lymphatic system and intercellular spaces. Such T cells have immunologic specificity, they can recognize and react with antigens and also distinguish between "self" and "non- self" during cell-mediated immune response (e.g., graft rejection) . These T cells express high levels of the cell surface marker T cell receptor (TCR) and are segregated into two major subclasses of CD4-positive and CD8-positive cell populations. When T cells encounter an antigen which is recognized by the T cell receptor on their surface, they are stimulated to divide and proliferate so that many more T cells of the same antigen specificity are produced. This process of T-cell activation enables the activated T cells to perform different tasks.
Several subclasses of mature T cells have been recognized based on the different tasks they perform. Helper cells (T, ) are required for promoting or enhancing B-cell antibody production. Cytotoxic/effector or killer cells (T. ) directly kill their target cells, usually virally infected, malignant or otherwise altered cells. Suppressor cells (T ) suppress or down-regulate immunological reactions. Most of the T, cells express the CD4 antigen whereas the T J, and Ts cells express the CD8 antigen, Swain, "T-cell Subsets and the Recognition of MHC Class", Immunol. Rev., 7:129 (1983) .
T cells respond specifically to the antigen on the surface of target cells which is associated with major histocompatibility complex (MHC) antigens. MHC antigens are
expressed on most human cells. MHC is divided into three classes (I-III) of antigens, Steinmetz et al., "Genes of the Major Histocompatibility Complex in Mouse and Man", Science, 222:727 (1983). MHC class I antigens include human leukocyte antigens (HLA-A, -B and -C) . Recent reports suggest that on many cell types studied, there is a physical association between MHC antigens and other cell surface proteins with receptorial activities. The review article entitled, "Function by Association?", M. Edidin, Immunology Today, 9:218-219 (1988) concludes that although there may be spatial associations between MHC Class I antigens and other T cell surface proteins, the function of these associations remains unknown.
The majority of human cytotoxic and suppressor T cells express the cell surface protein CD8. T cells expressing CD8 are herein designated CD8 cells. CD8 is thought to be involved in the process of T-cell recognition and activation, serving as an important element in MHC class I-restricted immune response. For review see, Engleman et al., "Activation of Human T Lymphocyte Subsets: Helper and Suppressor/Cytotoxic T cells Recognize and Respond to Distinct Histocompatibility Antigens", J. Immunol., 127:2124
(1981); Meuer et al., "Clonal Analysis of Human Cytolytic T Lymphocytes: T4 + and T8+ Effector T Cells Recognize Products of Different Major Histocompatibility Complex Regions",
Proc. Natl. Acad. Sci. USA, 79:4395 (1982); Swain, "T-cell Subsets and the Recognition of MHC Class", Immunol. Rev., 74:129 (1983). T cells are known to be activated when CD8 interacts on the cell surface with the T cell receptor complex, Emmrich et al., "Synergism in the Activation of Human CD8 T cells by Cross-linking the T-cell Receptor Complex With the CD8 Differentiation Antigen", Proc. Natl. Acad. Sci. USA, 83:8298 (1986). Nevertheless, the precise
role of CD8 in T-cell recognition and activation remains unclear.
Recently, CD8 and the MHC Class I heavy chain antigens have been found to be noncovalently associated on the surface of antigen- or mitogen-activated human T cells but the functional role of this molecular complex was not determined, Bushkin et al., "Physical Association Between. CD8 and HLA Class I Molecules on the Surface of Activated Human T Lymphocytes", Proc. Nat'l. Acad. Sci. USA, 85:3985- 3989 (1988); and Blue et al. , "Evidence for Specific Association Between Class I Major Histocompatability Antigens and the CD8 Molecules on Human Suppressor/Cytoxic Cells", 54:413-421 (1988).
SUMMARY OF THE INVENTION
It has now been found that the cross-linking of at least two molecules on the surface of a mature human T cell results in activation of this T cell and subsequent vigorous proliferation in the presence of interleukin-2.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 shows the kinetics of proliferative responses of CD8-MHC class I cross-linked CD8 cells.
DETAILED DESCRIPTION OF THE INVENTION
This invention is based on the finding that noncovalent complexes of CD8 and MHC class I antigens are found on activated human cytotoxic/suppressor T cells.
Accordingly, it has been found that noncovalent cross-linking of CD8 and MHC class I antigens on the surface of resting CD8 cells can activate these T cells and stimulate their proliferation in response to for example interleukin-2 (IL-2) .
Cross-linking of T cell surface molecules can be accomplished by any known means of associating molecules of this type. For example, the use of primary antibodies or parts thereof which bind to T cell surface proteins and subsequent cross-linking of the primary antibodies with secondary antibodies serves to noncovalently associate T cell surface proteins. The same results could be achieved by the use of hetero-conjugate (hybrid) antibodies. Hybrid antibodies can be generated by chemical cross-linking of anti-CD8 and anti-MHC class I antibodies, or by "hybrid" hybridomas obtained by the fusion of parental hybridomas secreting anti-CD8 and anti-MHC class I antibodies.
In a preferred embodiment of this invention, CD8 and MHC class I antigens on the same activated CD8 cell are noncovalently associated. However, it is believed that any means of covalent association such as that achieved by chemical cross-linking could also be used.
Preferably cross-linking of CD8 and MHC class I antigens on a CD8 cell is accomplished by a two step method. The first step is to incubate a CD8 cell sample with at least one of the monoclonal antibodies (mAb) specific for CD8 (C8, OKT8A and anti-Leu-2a) and with at least one of the mAb specific for MHC class I antigens (PA2.6, BB7.7 and A1.4). The first set, or primary, mAb are allowed to bind to their respective antigens (CD8 and MHC class I) and then the excess, unbound, mAb is washed away from the cells. In the second step, the mAbs bound to the CD8 and MHC class I antigens on the cell surface are brought into close proximity to cause a noncovalent association of CD8 and MHC class I antigens. This is accomplished by addition of a secondary antibody to the cells coated with primary mAb. A suitable secondary antibody is a polyclonal affinity- purified goat anti-mouse IgG (GaMIg) antibody which recognizes and binds to the unbound Fc-portion of the
primary mAb. The noncovalent association between CD8 and MHC class I antigens approximated by anti-CD8, anti-MHC class I and secondary antibodies is due to some degree of structural homology between CD8 and MHC class I antigens, Littman et al. , "The Isolation and Sequence of the Gene Encoding T8: a Molecule Defining Functional Classes of T Lymphocytes", Cell, 40:237-246 (1985); and Anderson et al., "Regulatory Interactions Between Members of the Immunoglobulin Superfamily", Immunol. Today, 9:199-203 (1988) .
Cross-linking of CD8 and MHC class I antigens as described above results in a marked proliferation of resting human CD8 cells in the presence of IL-2. To a lesser extent, CD8 cell activation and proliferation can also be induced by cross-linking of MHC class I antigens to themselves (Fig. 1 and Table I) . Activation of CD8 cells by cross-linking of CD8 and MHC class I antigens is accompanied by expression of both IL-2 receptor and the MHC class II (HLA-DR and -DQ) antigens as demonstrated by immunoprecipitation and sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The presence of these antigens is indicative of the T-cell activation. Activation of CD8 cells by cross-linking is apparently independent of accessory monocytes. Various anti-CD8 and anti-MHC class I mAb which recognize nonpolymorphic antigenic determinants can be used to activate CD8 cells. Surprisingly, not all mAb induce proliferation to the same extent. Among mAb specific for the MHC class I antigens, PA2.6, BB7.7 and A1.4 mAb together with anti-CD8 mAb, markedly stimulated the proliferation of CD8 cells, W6/32 mAb showed a weak stimulation, whereas BBM.l, Ql/28 and HC10 mAbs failed to induce proliferation (Table II) . In contrast to the anti-MHC class I mAb, all anti-CD8 mAb examined (C8, 0KT8A and anti-Leu-2a) induced
the proliferation of CD8-MHC class I cross-linked cells with similar efficacy. These results suggest that physical interaction between CD8 and at least one specific determinant of MHC class I antigens can trigger the activation of resting human CD8 cells.
It is believed that CD8 cells activated in such a way become functionally competent cytotoxic and/or suppressor T cells. This novel method of T-cell activation could therefore be of great importance in generating activated T cells for therapeutic purposes, similar to the use of lymphokine-activated killer and tumor-infiltrating T lymphocytes in cancer therapy, Oehoa et al., "Lymphokine- Activated Killer Activity in Long-Term Cultures with Anti- CD3 Plus Interleukin 2: Identification and Isolation of Effector Subsets", Cancer Research, 49:963-968 (1989); and Rosenberg et al. , "Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma", N. Engl. J. Med. , 319:1676-1680 (1988) . Thus, activated cytotoxic effector T cells generated by cross-linking of CD8 and MHC class I antigens may be used in the treatment of cancer and viral infections in mammals including humans, whereas suppressor T cells activated in this manner may be effective in the treatment of autoimmune diseases. In addition, the presence of CD8-MHC class I molecular complex on the T cell surface may serve as a marker for certain stages of T-cell activation, and as such, be useful in clinical diagnosis of various disease states and in the follow-up control of various anti-cancer and immunodeficiency treatments.
One obvious advantage of our method is that T cells could be activated both in vitro and in vivo in mammals including humans. However, activation of human T cells in vivo would require some modifications, for
example, hybrid anti-CD8/MHC class I mAb, if used, would need to be produced by human hybridomas rather than by murine hybridomas.
This invention will be better understood by reference to specific examples which are given for purposes of illustration and are not meant to limit the invention.
Example 1
Purification of CD8 Cells Peripheral blood mononuclear cells were isolated from buffy coats of healthy donors by gradient centrifugation on Ficoll-Hypaque (Isolymph, Gallard- Schlesinger Chemical Mfg. Corp. , Carle Place, NY) . T lymphocytes were separated from non-T cells by rosetting with neuraminidase (Sigma)-treated sheep red blood cells at 4°C for 1 hr. , Kansas et al., "Functional Characterization of Human T Lymphocyte Subsets Distinguished by Monoclonal Anti-Leu8", J. Immunol., 134:2995 (1985). After separation on a Ficoll-Hypaque gradient, rosetted cells were recovered by treatment with Tris-buffered ammonium chloride. Purified CD8 cells were prepared by negative selection using a panning technique as previously described, Wysocki et al., "'Panning' for Lymphocytes: A Method for Cell Selection", Proc. Natl. Acad. Sci. USA, 75:2844 (1978). Briefly, unfractionated T cells were treated with anti-Leu-3a mAb, and then washed and incubated in affinity-purified GaMIg- coated panning dishes at 4CC for 2 hr as described by Engleman et al. , "Activation of Human T Lymphocyte Subsets: Helper and Suppressor Cytotoxic Cells Recognize and Respond to Distinct Histocompability Antigens", J. Immunol., 127:424 (1981) .
Nonadhered CD8 cells were collected, and contaminating monocytes were depleted by repeated adherence to tissue culture flasks at 37°C. Monocytes were further
depleted by treatment with L243 mAb (IgG2a) at 4°C for 30 min, and then with 10% rabbit complement (Low-Tox-H, Cedarlane Laboratories, Ontario, Canada) at 37°C for 1 hr with frequent agitation. The phenotypic profile of the purified CD8 cells was determined by fluorescence activated cell sorter (FACS) analysis (Ortho System 50H Cytofluoro- graph, Ortho Diagnostics Systems, Inc., Westwood, MA) and was determined to be as follows: >90% CD8 , >93% CD3 , <8%
CD4 +, and <1.5% Leu-M3+ cells. After exhausti.ve depletion of monocytes with L243 mAb plus complement, the Leu-M3 cells were reduced to <0.5%, and the CD8 cells thus obtained failed to proliferate when cultured for 3 days in the presence of 0KT3 mAb.
Example 2
Cell Culture and Proliferation Assay
The purified CD8 cells prepared according to Example 1 were suspended at 10 cells/ml in RPMI 1640 medium supplemented with 10% fetal bovine serum, glutamine (0.06 mg/ml) , streptomycin (0.1 mg/ml) and penicillin (100 U/ml) (hereafter, culture medium) and were incubated with 10-15 μg/ml of various mAb for 1 hr at room temperature.
Various anti-CD8 and anti-MHC class I antigen mAb were used. 0KT8A (IgG2a, Ortho Diagnostics, Raritan, NJ) , anti-Leu-2a (IgGl, Becton Dickinson, Mt. view, CA) and C8 (IgG2a, Dr. C.Y. Wang, United Biomedical, Lake Success, NY) are specific for human CD8. W6/32 (IgG2a) , PA2.6 (IgGl), BB7.7 (IgG2b) (American Type Culture Collection (ATCC) , Rockville, MD) . A1.4 (IgGl), HC10 (IgG2a, Dr. N.J. Stam, the Netherlands Cancer Institute, the Netherlands) and Ql/28 (IgG2a, Dr. C. Russo, Cornell University Medical College, New York, NY) are directed against the MHC class I HLA-A, -B and -C antigens. BBM.l (ATCC) is an IgG2b mAb recognizing β -microglobulin (β2~\) . All anti-CD8 and anti-
MHC class I antigen mAb were equilibrated with respect to the concentration of mouse immunoglobulin.
After precoating with mAb, cells were washed twice and seeded in flat-bottomed 96-well microtiter plates at 5x10 4 or 1x105 cells/ well i.n 200 μl culture medium.
Unless noted otherwise, affinity-purified GaMIg (Organon
Teknika Corp., West Chester, PA) (2.5 /.g/ml) and/or recombinant human IL-2 (Boehringer Mannheim, W. Germany) (10
U/ml) were added to the cell cultures. The cells were cultured at 37°C for 5 days, and pulsed with 1 /_.Ci/well of [ 3H]thymι.dι.ne ([3H]TdR) , (6.7 Ci/mmol; New England Nuclear
Corp., Boston, MA) 16 hr prior to harvest. Results were
3 eexxpprreesssseedd iinn ccoouunnttss ppeerr mmiinnuuttee ((qcpm) as mean [ H]TdR uptake of triplicate determinations +SD.
Example 3
Cross-linking of CD8 and MHC Class I Antigens
In order to induce the proliferation of CD8 cells in response to IL-2, CD8 and MHC class I molecules on the surface of CD8 cells were cross-linked. This was done by first incubating CD8 cells prepared according to Example 1 with anti-CD8 and/or anti-MHC class I mAb, and then reacting with GaMIg as described in Example 2.
As seen in Table I, CD8-MHC class I cross-linked cells markedly proliferated in response to IL-2 as determined by [ H]TdR uptake. Both GaMIg and IL-2 are essential for the proliferation of CD8 cells. The effect of IL-2 on CD8 cell proliferation is dose-dependent: an increase in IL-2 concentration from 10 U/ml to 100 U/ml resulted in an up to 8-fold increase in cell proliferation. Likewise, the proliferation of CD8 cells also depends on the concentration of GaMIg added, with as little as 0.25 μg/ral of GaMIg inducing a 3-fold increase in T cell proliferation. As was shown for CD4 cells, Geppert et al., "Activation of
Human T Cells by Cross-linking Class I MHC Molecules", J. Immunol. 140:2155 (1988), cross-linking of MHC class I antigens alone by A1.4 mAb and GaMIg resulted in a moderate proliferation of CD8 cells, which was significantly lower than that of CD8-MHC class I cross-linked CD8 cells. In contrast, cross-linking of CD8 molecules alone using C8 mAb and GaMIg failed to induce significant proliferation (Table I and Figure 1) .
In Table I, uncoated CD8 cells or cells precoated with mAb C8, A1.4 or C8 and A1.4 in combination, were cultured at 5x10 4 cells/well i.n culture medi.um in 96- well plates for 5 days in the presence or absence of GaMIg and/or IL-2 as described in Example 2.
TABLE I
Stimulation of CD8 Cell Proliferation by Cross-Linking of CD8 and MHC Class I Antigens
Addition of [ H]TdR uptake (mean cpm +SD) of CD8 cells coated with
GaMIg IL-2 none C8 A1.4 C8+A1.4
170+85 183+75 144+37 122+12
227+105 ND ND 167+8
+ 201+53 ND ND 111+21
+ 309+50 623+119 2136+184 7861+133
The CD8 cell population vigorously depleted of monocytes by treatment with L243 mAb and complement, also proliferated after cross-linking of CD8 and MHC class I
antigens, suggesting that the activation of CDS cells is independent of accessory cells. It was noted, however, that addition of a small quantity of autologous monocytes to these cells dramatically increased their proliferative response, perhaps due to an IL-2-mediated, monocyte- dependent T cell proliferation.
Kinetic studies, shown in Figure 1, demonstrated that cross-linking of CD8 and MHC class I antigens induced a marked proliferative response of CD8 cells as early as day 3, and reached a plateau on day 5. Cross-linking of MHC class I antigens alone showed similar kinetics with a less marked proliferative response. Cross-linking of CD8 alone failed to stimulate the proliferation of CDS cells.
In Figure 1, CD8 cells were first incubated in culture medium alone (+) , with OKT3 (open triangle) , C8
(open square), A1.4 (black triangle) or a mixture of C8 and A1.4 mAb (black square), then washed and cultured in the presence of GaMIg and IL-2 as described in Example 2. IL-2 was omitted in CD8 cells cross-linked with OKT3 mAb. Example 4
Expression of IL-2R and MHC Class II Antigens by Activated T Cells
It is known that T cells activated by antigen or mitogen express IL-2 receptor (IL-2R) and MHC class II anti- gens, Cotner et al., "Simultaneous Flow Cytometric Analysis of Human T-cell Activation Expression Antigen Expression and DNA Content", J. Exp. Med. , 157:461 (1983); and Robbins et al. , "Activated T Cells and Monocytes Have Characteristic Patterns of Class II Antigen Expression", J. Immunol., 141:1281 (1988). To determine whether cross-linking of CD8 and MHC class I antigens also induces the expression of these activation markers, CD8-MHC class I cross-linked CD8 cells and control, untreated CD8 cells were cultured in the presence or absence of GaMIg and/or IL-2 for 5 days as
described in Example 2. The cells were then radioiodinated, and the cell lysates were reacted with anti-Tac (anti-IL- 2R) , and 1D1 and anti-Leu-io (anti-MHC class II) mAb followed by SDS-PAGE analysis. Radioiodination, immunoprecipitation and SDS-PAGE procedures are described in more detail as follows. Aliquots of 10 7 cells were radioiodinated by the lactoperoxidase method according to the manufacturer's instructions with 2 mCi of [ 125I] (100 mCi/ml; Amersham Corp., Arlington Heights, IL) . Cells were then lysed with 2 ml of isotonic phosphate-buffered saline, pH 8.3/0.5% Nonidet P-40/1 mM phenylmethylsulfonyl flouride/10 mM iodoacetamide according to Bushkin et al., "A New HLA-linked T Cell Membrane Molecule, Related to the' β Chain of the Clonotypic Receptor, is Associated With T3", J. Exp. Med. , 164:458 (1986). After depletion of free iodide by passage through a 0.2 ml column of AG1X8C1- (Bio-Rad, Richmond, CA) , the lysates were absorbed twice with 300 μl of goat anti- mouse IgG-agarose beads (Sigma) alone and immunoprecipitated with 60 μl of goat anti-mouse IgG-agarose beads coated with specific mAb. The materials were eluted from the beads with Laemmli sample buffer, as previously described, Laemmli, "Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4", Nature, 227:680 (1970). The immunoprecipitated proteins were then analyzed by SDS-PAGE on vertical slab gels of 13% acrylamide under reducing conditions.
Results of this experiment showed that only CD8-MHC class I cross-linked CDS cells cultured in the presence of IL-2 were induced to express IL-2R, and the MHC class II HLA-DR and HLA-DQ antigens. These activation markers were not expressed in control CD8 cells, CD8 cells cultured with IL-2 alone, or CD8-MHC class I cross-linked CD8 cells cultured without IL-2.
Example 5
Effects of Different Anti-MHC Class I mAb on T Cell Activation
As shown in Table II, there is a marked variation in the ability of different anti-MHC class I mAb to stimulate the proliferation of CD8-MHC class I cross- linked cells. In this Table, CD8 cells precoated with mAb
C8 and/or various mAb specific for MHC class I antigen, were cultured at 5x10 4 or 1x105 per well i.n culture medi.um in 96-well plates for 5 days in the presence of GaMIg and IL-2 as described in Example 2. PA2.6, BB7.7 and A1.4 mAb induced potent proliferation of CD8-MHC class I cross-linked CD8 cells. W6/32 mAb exerted a weak stimulatory effect. On the other hand, BBM.l, HC10 and Ql/28 mAb did not stimulate the cells. It is unlikely that the difference in the ability of various anti-MHC class I mAb to stimulate the proliferation of cells was due to different binding affinity of the antibodies, as all the anti-MHC class I mAb were found to precipitate similar amount of MHC class I antigen from radioiodinated cell lysates. The ability of PA2.6, BB7.7 and A1.4 mAb to stimulate cross-linked CD8 cells is possibly related to the antigenic region (α2 domain of MHC class I antigen) these mAb recognize. Stimulation of cross-linked CD8 cell proliferation appears to be a highly specific process, which requires direct participation of CDS protein and at least one epitope of MHC class I antigen which is accessible upon binding of PA2.6, BB7.7 and A1.4 mAb. Therefore, it is likely that other mAb which recognize the MHC class I α2 domain could work in conjunction with anti-CD8 mAb to activate CDS cells.
TABLE II
Relevance of nonpolymorphic epitopes of MHC class I antigen to the activation of cross-linked CD8 cells
[ H]thymidine uptake (mean cpm +SD) of CDS cells cross-linked with
Cells/well C8 none BBM.l HC10 Ql/28 W6/32 A1.4 PA2.6 BB7.7
.xlO 122+2 260+48 ND . ND 460+11 724+45 2204+136 ND
167+8 295+36 ND ND 753+109 2483+74 5845+21 ND lxlO- 332+50 510+47 355+63 372+65 576+12 1262+14 1905+183 1206+89
658+53 652+53 385+44 463+52 1002+137 2453+161 4070+159 2540+14
Claims
1. A method of activating mammalian T cells comprising forming an association between at least two of the molecules located on the surface of the T cell.
2. The method according to claim 1 wherein the molecules are selected from the group consisting of CDS,
HLA-A, HLA-B and HLA-C.
3. A method of activating mammalian T cells comprising cross-linking T cell surface molecules using a primary antibody or parts thereof which recognizes T cells or parts thereof and subsequently noncovalently cross- linking the primary antibody attached to the T cell or parts thereof using a secondary antibody which recognizes and binds to the primary antibodies.
4. The method according to claim 3, wherein the T cell surface molecules are selected from the group consisting of CD8, HLA-A, HLA-B and HLA-C and the primary antibodies to T cells or parts thereof, are anti-CD8 antibody and anti-MHC class I antibody, and the secondary antibodies to the primary antibodies attached to the T cell surface molecules are antibodies to some region held in common by the primary antibodies.
5. The method according to claim 4 wherein the primary antibodies to T cells or parts thereof are mouse anti-human CDS antibody and mouse anti-human MHC class I antibody, and the secondary antibody to these primary antibodies is a goat antibody recognizing the Fc region of mouse antibody.
6. The method according to claim 5 wherein the primary antibodies are monoclonal antibodies, whereas the secondary antibody is a polyclonal antibody. 7. The method according to claim 6 wherein the monoclonal antibodies are selected from the group consisting of PA2.6, BB7.
7, A1.4, C8, OKT8A and anti-Leu-2a.
8. An activated mammalian T cell wherein at least two of the cell surface molecules selected from the group consisting of CD8, HLA-A, HLA-B and HLA-C are cross- linked.
9. An activated mammalian T cell according to claim 8 wherein the molecules are cross-linked using a primary antibody or parts thereof which recognizes T cells or parts thereof and subsequently noncovalently cross- linking the primary antibody attached to the T cell or parts thereof using a secondary antibody which recognizes and binds to the primary antibodies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35039289A | 1989-05-11 | 1989-05-11 | |
US350,392 | 1989-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990013629A1 true WO1990013629A1 (en) | 1990-11-15 |
Family
ID=23376507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/002649 WO1990013629A1 (en) | 1989-05-11 | 1990-05-09 | A method for the activation of t cells |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5678890A (en) |
IL (1) | IL94350A0 (en) |
WO (1) | WO1990013629A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0448057A1 (en) * | 1990-03-19 | 1991-09-25 | Bristol-Myers Squibb Company | Monoclonal antibody reactive with a novel HLA determinant on MHC class I molecules and method for activating lymphocytes |
WO1995007995A2 (en) * | 1993-09-13 | 1995-03-23 | Applied Immune Sciences, Inc. | Adeno-associated viral (aav) liposomes and methods related thereto |
US5601828A (en) * | 1989-03-15 | 1997-02-11 | Tkb Associates Limited Partnership | CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
US5623056A (en) * | 1989-03-15 | 1997-04-22 | Tkb Associates Limited Partnership | CDS derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
US6652850B1 (en) | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
WO2017015024A1 (en) * | 2015-07-20 | 2017-01-26 | Mayo Foundation For Medical Education And Research | Methods and materials for producing t cells |
-
1990
- 1990-05-09 AU AU56788/90A patent/AU5678890A/en not_active Abandoned
- 1990-05-09 WO PCT/US1990/002649 patent/WO1990013629A1/en unknown
- 1990-05-10 IL IL94350A patent/IL94350A0/en unknown
Non-Patent Citations (4)
Title |
---|
Proc. Natl. Acad. Sci. USA, Vol. 85, June 1988, (Washington, DC, US), Y. BUSHKIN et al.: "Physical Association between the CD8 and HLA Class I Molecules on the Surface of Activated Human T Lymphocytes", pages 3985-3989 see the whole article cited in the application * |
The Journal of Immunology, Vol. 139, No. 10, 15 November 1987, The American Association of Immunologists, (Baltimore, MD, US), S. TAKADA et al.: "Evidence for an Assication between CD8 Molecules and the T Cell Receptor Complex on Cytotoxic T Cells", pages 3231-3235 see the Abstract * |
The Journal of Immunology, Vol. 142, No, 12, 15 June 1989, The American Association of Immunologists, (Baltimore, MD, US), M.C. WACHOLTZ et al.: "Patterns of Costimulation of T Cell Clones by Crosslinking CD3, CD4/CD8, and Class I MHC Molecules", pages 4201-4212 see the whole article * |
The Journal of Immunology, Vol. 142, No. 11, 1st June 1989, The American Association of Immunologists, (Baltimore, MD, US), T.D. GEPPERT et al.: "Activation of Human T Cell Clones and Jurkat Cells by Cross-Linking Class I MHC Molecules", pages 3763-3772 see the Abstract; table III * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5601828A (en) * | 1989-03-15 | 1997-02-11 | Tkb Associates Limited Partnership | CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
US5623056A (en) * | 1989-03-15 | 1997-04-22 | Tkb Associates Limited Partnership | CDS derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
EP0448057A1 (en) * | 1990-03-19 | 1991-09-25 | Bristol-Myers Squibb Company | Monoclonal antibody reactive with a novel HLA determinant on MHC class I molecules and method for activating lymphocytes |
WO1995007995A2 (en) * | 1993-09-13 | 1995-03-23 | Applied Immune Sciences, Inc. | Adeno-associated viral (aav) liposomes and methods related thereto |
WO1995007995A3 (en) * | 1993-09-13 | 1995-07-20 | Applied Immunesciences | Adeno-associated viral (aav) liposomes and methods related thereto |
US5834441A (en) * | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
US5861314A (en) * | 1993-09-13 | 1999-01-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
US5861171A (en) * | 1993-09-13 | 1999-01-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
US6652850B1 (en) | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
WO2017015024A1 (en) * | 2015-07-20 | 2017-01-26 | Mayo Foundation For Medical Education And Research | Methods and materials for producing t cells |
US10624925B2 (en) | 2015-07-20 | 2020-04-21 | Mayo Foundation For Medical Education And Research | Methods and materials for producing T cells |
US11266691B2 (en) | 2015-07-20 | 2022-03-08 | Mayo Foundation For Medical Education And Research | Methods and materials for producing T cells |
Also Published As
Publication number | Publication date |
---|---|
IL94350A0 (en) | 1991-03-10 |
AU5678890A (en) | 1990-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
London et al. | Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. | |
Vercelli et al. | Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. | |
Hara et al. | Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). | |
Chatenoud et al. | Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. | |
Lanier et al. | Evidence for three types of human cytotoxic lymphocyte | |
Lanier et al. | Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). | |
Young et al. | Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. | |
Phillips et al. | Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. | |
Gray et al. | Generation of an inhibitory circuit involving CD8+ T cells, IL-2, and NK cell-derived TGF-β: contrasting effects of anti-CD2 and anti-CD3 | |
Ruppert et al. | IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency | |
EP0765386B1 (en) | Methods for in vivo t cell activation by antigen-pulsed dendritic cells | |
GALIANI et al. | Expression of killer inhibitory receptors on cytotoxic cells from HIV‐1‐infected individuals | |
Bensussan et al. | Delineation of an immunoregulatory amplifier population recognizing autologous Ia molecules. Analysis with human T cell clones. | |
Chouaib et al. | Differential effect of anti-beta 2-microglobulin on IL 2 production and IL 2 receptor expression in the primary mixed lymphocyte culture reaction. | |
Morris Jones et al. | The response of γδ T cells to Plasmodium falciparum is dependent on activated CD4+ T cells and the recognition of MHC class I molecules | |
Pardi et al. | Lymphocyte subsets differentially induce class II human leukocyte antigens on allogeneic microvascular endothelial cells. | |
Lier et al. | Anti‐CD27 monoclonal antibodies identify two functionally distinct subpopulations within the CD4+ T cell subset | |
Ford et al. | Production of B cell growth factor (s) by neoplastic B cells from hairy cell leukemia patients | |
WO1990013629A1 (en) | A method for the activation of t cells | |
Lifson et al. | Purified interleukin-2 induces proliferation of fresh human lymphocytes in the absence of exogenous stimuli | |
Roberts et al. | A clonal analysis of human peripheral blood lymphocytes displaying natural killer‐like activity | |
Emilie et al. | Role of the LFA3-CD2 interaction in human specific B cell differentiation. | |
Morishita et al. | Antigen-specific functions of a CD4+ subset of human T lymphocytes with granular morphology. | |
Yi et al. | Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules | |
Warren et al. | Human natural killer (NK) cells: requirements for cell proliferation and expansion of phenotypically novel subpopulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU JP KR NO SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |